Rubius Therapeutics is a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to develop a class of cellular medicines called Red Cell Therapeutics for the treatment of cancer and autoimmune diseases. Co.'s platform, RED PLATFORM, biologically engineers and cultures allogeneic red blood cell therapies that enable multiple applications, or modalities. Co.'s immune stimulation for the treatment of cancer includes RTX-240, which is designed to stimulate the immune system by activating and expanding both NK and CD8+ memory T cells to generate an anti-tumor response; and RTX-224, which is designed as an immune agonist of both adaptive and innate responses. The RUBY average annual return since 2018 is shown above.
The Average Annual Return on the RUBY average annual return since 2018 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether RUBY average annual return since 2018 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the RUBY average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|